Market Watch Rx: Baxter International Leads Gainers
This article from PharmExec News reports on Baxter International leading the gainers in the pharma market. It also highlights other trending news in the pharmaceutical executive space, including Eli Lilly's acquisition of Engage Bio and discussions around machine learning in life sciences. The content primarily serves as a market update and a pointer to other popular articles on the platform.
Baxter International Inc. stock (US0673431090): spin-off hangover meets margin push
Baxter International is undergoing a significant portfolio and cost base reorganization following spin-offs like Kidney Care, while also navigating margin pressures and a cautious outlook. The company, which focuses on critical care and hospital products, aims to stabilize growth and cash flows by shifting towards higher-margin businesses and leveraging its installed equipment base to drive recurring revenue. This strategic transformation presents both opportunities for defensive investors seeking long-term growth and risks related to execution and regulatory challenges.
Baxter International Inc. stock outperforms competitors on strong trading day
Shares of Baxter International Inc. (BAX) increased by 1.39% to $19.03 on Thursday. This performance outpaced the broader market, with the S&P 500 Index (SPX) rising 0.17% and the Dow Jones Industrial Average (DJIA) gaining 0.55%. This gain marked the fourth consecutive day of increases for Baxter International stock.
CONMED Adds Former Johnson & Johnson and Boston Scientific Executives to Board
CONMED Corporation has announced the appointment of Celine Martin and Jeff Mirviss, former executives from Johnson & Johnson and Boston Scientific respectively, to its board of directors. These additions aim to bolster CONMED's strategic oversight and enhance its competitive edge in the MedTech industry, leveraging their extensive experience in surgical technology, global commercialization, and operational leadership. The appointments highlight the evolving governance priorities in MedTech, which increasingly favor operational and commercialization expertise alongside financial oversight.
Baxter International Inc. stock (US0673431090): governance changes and board size reset in focus
Baxter International Inc. has implemented shareholder-approved changes to its charter and bylaws, resetting the parameters for its board size to a range of seven to twelve directors. This adjustment provides greater flexibility for board composition, aligning with the company's ongoing portfolio restructuring and separation plans. The article details Baxter's core business model, key revenue drivers, and the financial and industry context surrounding these governance changes for US investors.
Baxter International Inc. stock (US0673431090): spin-off hangover meets restructuring push
Baxter International Inc. is undergoing a significant transformation following the spin-off of its kidney care business, Vantive. The company reported lower sales in Q1 2026 due to the separation but achieved higher adjusted profits through cost savings and portfolio refocusing. Management is dedicated to streamlining operations, optimizing its portfolio, and maintaining financial flexibility through debt reduction and a stable dividend policy.
TD Cowen Maintains Baxter International Inc(BAX.US) With Hold Rating, Maintains Target Price $20
TD Cowen has reiterated its Hold rating for Baxter International Inc. (BAX.US), maintaining a target price of $20. This indicates a consistent outlook from the firm regarding Baxter's stock performance.
Baxter International Inc. stock outperforms competitors on strong trading day
Shares of Baxter International Inc. (BAX) rose 3.04% to $18.33 during a generally down market day where the S&P 500 Index and Dow Jones Industrial Average both fell. This marks the second consecutive day of gains for Baxter's stock. The company's performance stood out against its competitors despite the overall market decline.
Baxter Board Size Reset Puts Governance Changes In Focus For Investors
Baxter International recently received shareholder approval to amend its certificate of incorporation and bylaws, allowing greater flexibility in board size, now ranging from seven to twelve directors. This governance change comes after a prolonged period of weak share performance for BAX and is seen as an effort to align board oversight with new strategic priorities and shareholder feedback. Investors will be watching for new director appointments and policy changes to gauge the impact of this reset on the company's future performance and financial health.
Baxter Board Size Reset Puts Governance Changes In Focus For Investors
Baxter International (NYSE:BAX) recently received shareholder approval to amend its certificate of incorporation and bylaws, adjusting the framework for its board size to between seven and twelve directors. This governance change is viewed as a tool to reshape oversight and potentially bring in fresh expertise, especially in light of the company's weak share performance over the past five years. Investors are now watching for future announcements regarding new director appointments, committee reshuffles, or changes in capital allocation policies to assess how this flexibility will be utilized to address operational and financial challenges.
Baxter stock (US0673431090): FDA update puts focus on hospital-device demand
Baxter International is gaining attention due to a recent FDA-related development impacting its hospital and kidney-care segments. The company's business model, heavily reliant on essential medical therapies, makes its stock a key indicator for investors monitoring demand for medical devices, regulatory risks, and reimbursement trends in the U.S. healthcare market. Its performance is often evaluated based on execution, quality systems, and margin recovery, making it a monitoring stock rather than a high-growth momentum play.
BAX (NYSE: BAX) affiliate files notice listing prior open-market purchases
An affiliate of Baxter International Inc. (BAX) utilizing Morgan Stanley Smith Barney LLC as a broker, has filed a Form 144 notice for proposed sales of common stock. The filing details multiple past open-market purchases with specific dates and share counts, noting 36,347 shares with a monetary figure of $645,235.58. This neutral filing helps ensure transparency regarding upcoming stock sales.
Baxter International Inc. stock outperforms competitors on strong trading day
Baxter International Inc. (BAX) stock increased by 2.83% to $17.79 on Monday, outperforming its competitors. This rise occurred during a mixed trading session where the Dow Jones Industrial Average gained, but the S&P 500 Index declined. The company's shares are currently 44.48% below their 52-week high.
CVS Earnings Story Gains Fresh S&P 500 Attention
The latest CVS Health earnings discussion has brought renewed attention to its healthcare operations within the S&P 500. The discussion highlighted unusual expenses and operational resilience, prompting questions about earnings quality and long-term stability. The article aims to delve into these aspects and their implications for the broader healthcare market.
Medical Adhesives Research and Forecast Report 2026-2035: $23+ Bn Market is Fiercely Competitive, Featuring Giants Like 3M Company, Avery Dennison, Baxter, Dow Chemical, H.B. Fuller, and Henkel
The global medical adhesives market is projected to grow from $13.01 billion to $23.04 billion by 2035, driven by increased minimally invasive surgeries, advanced wound care demand, and wearable technology. Key drivers include an aging population, rising chronic diseases, and continuous advancements in adhesive technology, with Asia dominating the market. The market is highly competitive, featuring major players like 3M, Avery Dennison, Baxter, Dow Chemical, H.B. Fuller, and Henkel, who are focusing on eco-friendly, biocompatible, and smart adhesive innovations despite regulatory and economic challenges.
Baxter International Inc. (BAX) Stock Analysis: Exploring a 27.83% Potential Upside Amidst Healthcare Sector Dynamics
Baxter International Inc. (BAX) operates in the medical instruments and supplies industry with a market cap of $8.93 billion. Despite a recent marginal decline in stock price and negative EPS, analysts see a potential upside of 27.83% to an average target price of $22.12. The company faces financial challenges, indicated by its negative ROE and high dividend payout ratio, but possesses strong free cash flow providing liquidity for growth.
Is Baxter International (BAX) Pricing Reflect A Turn After Steep Multi Year Share Price Declines
Baxter International (BAX) has experienced steep share price declines over multiple years. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 33.4%, estimating an intrinsic value of $25.96 per share compared to its current price of $17.30. Additionally, its Price/Sales (P/S) ratio of 0.79x is significantly lower than the industry average, further indicating it may be undervalued based on revenue metrics.
Baxter International stock (US0673431090): News flow turns after fresh market moves
Baxter International recently garnered market attention due to a stock move, highlighting rapidly changing sentiment for the healthcare company. As a key player in hospital products and renal care, its performance is closely watched by U.S. investors and reflects broader healthcare trends. The article emphasizes that Baxter's business model, rooted in providing essential products for acute and chronic care, makes it relevant to ongoing healthcare utilization and market dynamics.
Harrow’s TRIESENCE Phase 3 Milestone Adds New Dimension To Growth Story
Harrow has received FDA clearance for its Investigational New Drug application for TRIESENCE, allowing a Phase 3 clinical trial for ocular inflammation and pain after cataract surgery to proceed. This milestone provides a new clinical catalyst for the company, diversifying its growth story beyond earnings guidance. While the trial adds to R&D costs and potential losses, a successful outcome could open up a significant market and reduce reliance on its current product portfolio, such as VEVYE and IHEEZO.
Artivion Q1 2026 Earnings: Revenue Matches Estimates, EPS Misses by 35% - News and Statistics
Artivion's Q1 2026 earnings saw revenue of $116.3 million, matching analyst estimates, but adjusted EPS missed expectations by 35.1% at $0.08 versus $0.12. The company attributed the shortfall to weak stent graft sales and delays in AMDS starter set sales due to hospital procurement issues, leading to a downward revision in full-year revenue and EBITDA guidance. Analysts questioned management on the conservatism of the revised guidance and the impact of future PMA approval for AMDS.
Axogen (AXGN) Valuation Check After Strong Recent Share Price Momentum
Axogen (AXGN) has seen strong recent share price momentum, with a 3-year return over 3x, and is considered 19.3% undervalued by its most followed narrative, suggesting a fair value of $50.78 per share due to anticipated FDA approval for Avance Nerve Graft and resultant market exclusivity. However, its current P/S ratio of 9.2x is significantly higher than the industry average, indicating a premium valuation and potential risk if growth or regulatory progress falters. Investors are encouraged to assess the balance of risk and reward by looking at the company's financials for themselves.
Baxter International stock (US0718131099): Q1 update highlights mixed sales and margin pressure
Baxter International reported mixed Q1 results with softer sales in some units and continued margin pressure, impacting investor focus on the medtech company. The company's performance is tied to healthcare utilization, procurement cycles, and reimbursement conditions, making execution and margin recovery central to its outlook. Investors are watching for signs that revenue growth translates into operating leverage, particularly given Baxter's significant presence in the U.S. healthcare system through its renal care, hospital products, and infusion systems.
West Pharmaceutical Cyberattack Tests Operational Resilience And Investor Risk Assumptions
West Pharmaceutical Services (NYSE:WST) experienced a material cybersecurity incident involving data exfiltration and system encryption, leading to a temporary suspension of global operations. This event prompts investors to consider not just temporary downtime, but also potential regulatory scrutiny, data privacy obligations, and legal claims, challenging the company's operational resilience narrative. The article advises focusing on the speed of operational restoration, disclosures about accessed data, and the cost of remediation to assess the long-term impact on WST's stock.
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
SpyGlass Pharma announced its Q1 2026 financial results and provided corporate updates, highlighting progress in its BIM-IOL System and BIM-DRS programs. The company reported successful topline 12-month data from the BIM-IOL System Phase 1/2 trial, showing significant IOP reduction and elimination of topical eye drops for most participants. Following its IPO in February 2026, SpyGlass Pharma is well-funded, with $251.0 million in cash, expected to support operations through 2028.
Baxter International Inc. stock underperforms Friday when compared to competitors
Shares of Baxter International Inc. (BAX) fell 2.70% to $17.30 on Friday, underperforming the broader market as the S&P 500 Index and Dow Jones Industrial Average also experienced declines. The company's stock closed 46.00% below its 52-week high of $32.04, which was reached on June 11th. The downturn occurred during a generally negative trading session for the stock market.
BofA Securities Maintains Baxter International Inc(BAX.US) With Hold Rating, Maintains Target Price $24
BofA Securities has maintained its Hold rating on Baxter International Inc (BAX.US) and reiterated a target price of $24. This indicates the firm's view that the stock will likely perform in line with the broader market.
Baxter International Inc. stock (US0673431090): pharma supplier in focus after latest price swings
Baxter International Inc. (BAX) has experienced renewed volatility, with prices fluctuating around $17.70 in May 2026. The company, a medical technology and hospital-products supplier, focuses on infusion systems, renal care, and clinical nutrition, generating revenue through a mix of capital equipment and recurring consumables. Despite its integrated role in the healthcare system and global reach, Baxter faces challenges from regulatory risks, competitive pressures, and the need for continuous innovation to maintain market position.
DexCom Stock Draws Bullish Targets As Governance Shifts
DexCom Inc. (DXCM) stock has risen over 6% due to strong diabetes device demand and analyst upgrades, also driven by activist investor engagement leading to new independent directors and an Operations and Innovation Committee focused on long-term growth and margin strategy. Analysts have reaffirmed bullish ratings, with price targets as high as $100, citing strong Q1 organic sales growth, improved operating margins, and potential catalysts like Medicare CGM coverage and broader type 2 diabetes reimbursement. The stock is currently trading in a tight but tradeable range, underpinned by solid fundamentals and a strategic partnership with Elliott Management ahead of its 2026 Investor Day.
Artisan Value Income Fund's Baxter International Inc(BAX) Holding History
This article details Artisan Value Income Fund's historical holdings in Baxter International Inc (BAX). As of December 31, 2025, the fund held no shares, after initially purchasing 8,192 shares between 2023Q1 and an average price of $40.68, and selling all shares at an average price of $19.96. The estimated gain on these holdings is a loss of $-169,733.13, or -50.93%.
Baxter International Inc. stock outperforms competitors on strong trading day
Baxter International Inc. (BAX) shares rose 2.72% to $17.78, outperforming the broader market which also saw gains in the S&P 500 and Dow Jones Industrial Average. The company's stock closed 44.51% below its 52-week high of $32.04. This strong performance occurred on a generally positive trading day for the stock market.
Baxter International Inc. stock (US0673431090): Down 3.2% amid conference presentation
Baxter International Inc. shares dropped 3.2% to $17.31 on May 13, 2026, following its presentation at the Bank of America Global Healthcare Conference. Despite the decline, the stock is considered undervalued with a GF Score of 66/100. The company remains a key player in medical products and therapies, particularly in renal care and hospital products, with its business model focused on innovation in dialysis and infusion therapies.
Fresenius Medical Care stock (DE0005785802): Global dialysis leader for US investors
Fresenius Medical Care, a global leader in dialysis products and services, plays a significant role in the chronic kidney disease market, particularly for US investors due to its extensive North American operations. The company reported strong financial results for 2025, with €21.1 billion in revenue and solid profitability, reaffirming its position as the largest integrated provider of dialysis solutions. Its strategic focus on value-based care initiatives and a dominant market share position it well for continued growth in the expanding global dialysis market.
Fresenius Medical Care stock (DE0005785802): Global dialysis leader for US investors
Fresenius Medical Care, a global leader in dialysis, reported strong full-year 2025 results with €21.5 billion in revenue, driven by expanding patient bases and its integrated business model. The company holds a significant market share in dialysis products and services, particularly benefiting from its presence in the US healthcare market, which is crucial for US investors seeking defensive healthcare plays. Despite challenges like reimbursement changes and labor costs, its innovative therapies and global footprint position it for continued growth in the renal care sector.
Fresenius Medical Care stock (DE0005785802): Global dialysis leader for US investors
Fresenius Medical Care, a global leader in dialysis products and services, maintains a strong position in the chronic kidney disease market, with significant operations in the US. The company's business model relies on recurring revenue from dialysis treatments and its integrated vertical structure provides a competitive edge. US investors are particularly interested due to the company's defensive healthcare stock nature and its dominant presence in the North American market, influenced by US healthcare policies.
Baxter International Inc. stock underperforms Wednesday when compared to competitors
Shares of Baxter International Inc. (BAX) fell 3.24% on Wednesday, closing at $17.31, underperforming the broader market. This occurred on a mixed trading day where the S&P 500 Index rose, while the Dow Jones Industrial Average declined. The stock is currently 45.97% below its 52-week high.
Fresenius SE & Co. KGaA stock (DE0005785604): Global healthcare giant with US dialysis exposure
Fresenius SE & Co. KGaA, a German healthcare leader, maintains steady global operations, particularly in dialysis services through Fresenius Medical Care. The article highlights its relevance for US investors due to the NYSE-listed ADRs (FMS) and the significant patient base in North America. It details Fresenius' diversified business model, key revenue drivers from dialysis and other healthcare segments, and its competitive position in the industry.
Baxter International Inc. stock (US0673431090): Recent 2% price gain on NYSE
Baxter International Inc. stock saw a 2.05% price gain on May 12, 2026, closing at $17.89 on the NYSE. The article highlights the company's core business in renal care and hospital products for the US market, noting its relevance for American investors. Despite industry pressures, Baxter maintains a competitive edge and continues to be tracked by investors for its role in healthcare.
Baxter International Inc stock (US0718131099): Shares drop 2.56% to $17.53
Baxter International Inc (US0718131099) shares fell by 2.56% on May 11, 2026, closing at $17.53 on the NYSE. The decline occurred with high trading volume, reflecting ongoing market volatility in the healthcare sector. The company, a medical equipment maker, continues to navigate pressures amid its focus on hospital products and renal care solutions.
Baxter International Inc. stock underperforms Tuesday when compared to competitors despite daily gains
Baxter International Inc. (BAX) shares increased by 2.05% on Tuesday, closing at $17.89. Despite this daily gain, the stock underperformed compared to the broader market, with the Dow Jones Industrial Average rising and the S&P 500 Index falling marginally. The company's stock is currently 44.16% below its 52-week high of $32.04.
Fresenius Medical Care stock (DE0005785802): Global dialysis leader for US investors
Fresenius Medical Care (FMC) is a leading global provider of dialysis products and services, maintaining a strong presence in the US renal care market. The company's recent financial performance shows stability, with its integrated business model and focus on US operations contributing significantly to its revenue. FMC's stock offers US investors access to a defensive healthcare sector, leveraging its broad network of clinics and resilience against economic fluctuations.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2026 Earnings Call Transcript
Heron Therapeutics (NASDAQ:HRTX) reported its Q1 2026 earnings, missing EPS expectations at $-0.04 against an anticipated $-0.03, partially due to severe weather in January affecting elective surgeries. Despite seasonal headwinds and temporary gross margin pressure from a secondary supplier, the company reaffirmed its 2026 guidance, expecting net product sales between $173 million and $183 million and adjusted EBITDA of $10 million to $20 million, driven by strong growth in its Acute Care portfolio and strategic sales force expansion. Key growth drivers include the IGNITE program for ZYNRELEF and the inclusion of APONVIE in new consensus guidelines for postoperative nausea and vomiting.
Cardinal Health Extends Beyond Distribution With Surgical Case Cart Automation
Cardinal Health (NYSE:CAH) is expanding its involvement in the global surgical case carts market, indicating a strategic move into medical equipment and automation beyond its traditional distribution business. This shift aligns with trends in hospital automation, sterilization, and RFID tracking in surgical workflows. While investors have largely focused on financial results and distribution, the company's stock has seen significant gains, which may be partly driven by these new medical equipment activities.
Specialty Food Ingredients Market to Get an Explosive Growth | Cargill Inc, Ingredion Incorporated, Kerry Group
A new study by Coherent Market Insights projects explosive growth for the global Specialty Food Ingredients Market from 2026 to 2033. The comprehensive report analyzes market dynamics, key investment areas, competitive landscape, and growth drivers for strategic decision-making, offering insights into market size, revenue, and pricing trends. Key players analyzed include Cargill Inc., Ingredion Incorporated, and Kerry Group, with segmentation by ingredient type and application.
Fresenius Medical Care stock (DE0005785802): Latest developments in dialysis services
Fresenius Medical Care (FMC) reported stable performance in Q1 2026, with firm revenue in its core dialysis markets, driven by global demand for renal care services. The company, a leader in kidney care, focuses on vertically integrated dialysis products and services, particularly in North America, and is actively involved in home dialysis innovation and ESG initiatives. Despite regulatory pressures, FMC maintains a robust market position thanks to its extensive clinic network and strong US-centric earnings.
Baxter International Inc. stock underperforms Monday when compared to competitors
Baxter International Inc. (BAX) stock fell by 2.56% on Monday, closing at $17.53, despite an overall positive trading session for the market where the S&P 500 and Dow Jones Industrial Average both saw gains. This decline broke a four-day winning streak for the company.
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
Heron Therapeutics (Nasdaq: HRTX) announced its Q1 2026 financial results, reporting total net revenue of $34.7 million and reaffirming full-year 2026 guidance of $173–$183 million net revenue and $10–$20 million Adjusted EBITDA. The company saw strong year-over-year growth in its Acute Care franchise, driven by ZYNRELEF® and APONVIE®, and settled patent litigation with Baxter Healthcare Corporation involving CINVANTI®. Heron continues to expand its commercial efforts and advance its ZYNRELEF prefilled syringe lifecycle program.
Cardinal Health Extends Beyond Distribution With Surgical Case Cart Automation
Cardinal Health is expanding its business into the surgical case carts market, moving beyond its traditional distribution role into medical equipment and automation. This strategic shift aligns with growing trends in hospital automation and sterilization requirements, and is expected to diversify Cardinal Health's revenue streams. Investors are encouraged to monitor how this expansion in medical equipment impacts the company's financial performance and overall business mix.
Baxter International Inc. stock (US0673431090): Q1 2026 earnings beat consensus
Baxter International Inc. reported Q1 2026 earnings per share of $0.36, exceeding analyst estimates of $0.31, indicating a potential recovery for the medical products firm. The company's core business revolves around medical products and therapies, particularly in renal care and hospital products, serving a global market. This positive earnings beat, despite prior misses, positions Baxter as a relevant stock for US investors interested in the healthcare sector.
Becton Dickinson Wellstar Alliance Tests AI Hospital Medication Platform Narrative
Becton Dickinson (NYSE:BDX) has partnered with Wellstar Health System to implement AI-powered medication management and infusion technologies, including BD Pyxis Pro and BD Alaris systems, across Wellstar's facilities. This collaboration allows BD to test its connected care strategy and AI tools in a real-world setting, potentially serving as a proof of concept for other health systems. While the partnership presents execution risks related to complex software and AI, it offers significant rewards by providing a reference customer and supporting BD's growth in advanced patient monitoring and recurring, workflow-oriented revenue streams.
Baxter International Shareholders Approve Board Slate, Pay and Incentive Plan at Annual Meeting
Baxter International shareholders conducted their 2026 annual meeting virtually, where they gave preliminary approval to all five company proposals. These proposals included the election of nine directors, executive compensation, auditor ratification, an amended incentive plan, and a change related to board size. The company noted that final voting results will be disclosed in a Form 8-K within four business days.
